These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 10195253)

  • 1. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
    Ensoli B; Cafaro A
    J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-nef antibodies and other predictors of disease progression in HIV-1 seropositive injecting drug users.
    Rezza G; Titti F; Pezzotti P; Sernicola L; Lo Caputo S; Angarano G; Lazzarin A; Sinicco A; Rossi GB; Verani P
    J Biol Regul Homeost Agents; 1992; 6(1):15-20. PubMed ID: 1359736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters.
    Rezza G; Fiorelli V; Dorrucci M; Ciccozzi M; Tripiciano A; Scoglio A; Collacchi B; Ruiz-Alvarez M; Giannetto C; Caputo A; Tomasoni L; Castelli F; Sciandra M; Sinicco A; Ensoli F; Buttò S; Ensoli B
    J Infect Dis; 2005 Apr; 191(8):1321-4. PubMed ID: 15776379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.
    Reiss P; de Wolf F; Kuiken CL; de Ronde A; Dekker J; Boucher CA; Debouck C; Lange JM; Goudsmit J
    J Acquir Immune Defic Syndr (1988); 1991; 4(2):165-72. PubMed ID: 1898969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The prognostic markers of HIV infection progression. A study of the p24 antigen in a cohort of 251 patients].
    Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T
    An Med Interna; 1999 Sep; 16(9):447-50. PubMed ID: 10609356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
    Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
    Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical and immunological correlations between the p24 antigenemia levels and those of anti-p24 antibodies in HIV-seropositive children].
    Apetrei C; Buzdugan I; Mitroi I; Duca M
    Bacteriol Virusol Parazitol Epidemiol; 1995; 40(2):141-4. PubMed ID: 7549257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection.
    Richardson MW; Mirchandani J; Duong J; Grimaldo S; Kocieda V; Hendel H; Khalili K; Zagury JF; Rappaport J
    Biomed Pharmacother; 2003 Jan; 57(1):4-14. PubMed ID: 12642031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
    Rodriguez SK; Sarr AD; Olorunnipa O; Popper SJ; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Infect Dis; 2006 Sep; 194(6):760-3. PubMed ID: 16941341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Blood antigens and specific anti-core and anti-envelope antibodies as markers of the course of HIV infection].
    Sorice F; Vullo V; Cirelli A; Catania S; Mastroianni CM; Contini C; Delia S
    Boll Ist Sieroter Milan; 1989; 68(2):115-21. PubMed ID: 2562362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
    Cafaro A; Caputo A; Fracasso C; Maggiorella MT; Goletti D; Baroncelli S; Pace M; Sernicola L; Koanga-Mogtomo ML; Betti M; Borsetti A; Belli R; Akerblom L; Corrias F; Buttò S; Heeney J; Verani P; Titti F; Ensoli B
    Nat Med; 1999 Jun; 5(6):643-50. PubMed ID: 10371502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates.
    Mascarell L; Bauche C; Fayolle C; Diop OM; Dupuy M; Nougarede N; Perraut R; Ladant D; Leclerc C
    Vaccine; 2006 Apr; 24(17):3490-9. PubMed ID: 16524647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dynamics of the antibody response and p24 antigenemia in HIV-1 infected individuals in Czechoslovakia].
    Kopecká D; Brůcková M; Stanková M; Syrůcek L; Vojtĕchovský K; Petkov V
    Cesk Epidemiol Mikrobiol Imunol; 1990 Mar; 39(2):65-73. PubMed ID: 2142624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression.
    Martinez V; Costagliola D; Bonduelle O; N'go N; Schnuriger A; Théodorou I; Clauvel JP; Sicard D; Agut H; Debré P; Rouzioux C; Autran B;
    J Infect Dis; 2005 Jun; 191(12):2053-63. PubMed ID: 15897991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.